DRUG THERAPY OF ACUTE MYELOID LEUKEMIA

Martin S. Tallman, M.D.
Division of Hematology/Oncology
Department of Medicine
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Chicago IL  60611

D. Gary Gilliland, MD, Ph.D.
Division of Hematology/Oncology
Brigham and Women’s Hospital
Howard Hughes Medical Institute
Harvard Medical School
Boston, MA  02115

Jacob M. Rowe, M.D.
Department of Hematology and Bone Marrow Transplantation
Rambam Medical Center
Technion Israel Institute of Technology
Haifa, Israel  31096

Correspondence to:
Martin S. Tallman, M.D.
Northwestern Feinberg School of Medicine
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center
676 N. St. Clair Street, Suite 850
Chicago IL  60611
Tel: (312) 695-4540
Fax: (312) 695-6189
m-tallman@northwestern.edu
Abstract

While improvement in outcomes has occurred in younger adults with AML during the last four decades, progress in older adults has been much less conspicuous, if at all. Approximately 50-75% of adults with AML achieve complete remission (CR) with cytarabine and an anthracycline such as daunorubicin or idarubicin or the anthracenedione mitoxantrone. However, only approximately 20-30% of the patients enjoy long-term disease-survival. Various postremission strategies have been explored to eliminate minimal residual disease. The optimal dose, schedule and number of cycles of postremission chemotherapy for most patients are not known. A variety of prognostic factors can predict outcome, and include the karyotype of the leukemic cells, the presence of transmembrane transporter proteins which extrude certain chemotherapy agents from the cell and confer multidrug resistance and mutations in or over expressions of specific genes such as WT1, C/EBP[alpha], Bax, and Bcl-2/Bax ratio, BAALC, EVI1, KIT and Flt 3. Most recently, insights into the molecular pathogenesis of AML have led to the development of more specific targeted agents and have ushered in an exciting new era of antileukemia therapy. Such agents include: the immunoconjugate gemtuzumab ozogamicin, multidrug resistance inhibitors, farnesyl, transferase inhibitors, histone deacetylase and proteosome inhibitors, antiangiogenesis agents, Flt 3 inhibitors and apoptosis inhibitors.
Introduction

Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells and impaired production of normal hematopoiesis leading to neutropenia, anemia, and thrombocytopenia. If untreated, patients die of infection or bleeding usually in a matter of weeks. Some older adults may have a slower progressive clinical course. An estimated 10,600 new cases occurred in the United States in 2002 and 7,400 patients died from the disease. The overall incidence is 3.4 cases per 100,000 population; 1.2 cases per 100,000 population at age 30 and > 70 cases per 100,000 population at age 80 years. The median age is 70 years and has been increasing over the last decade.

Historically, the diagnosis and response to therapy were established based on morphology and cytochemistry. While morphology remains the initial diagnostic tool for any patient with acute leukemia, the past decade has witnessed increased reliance on cell surface antigen expression by immunophenotyping, usually carried out by flow cytometry, as well as cytogenetic and molecular markers.

During the last 4 decades, many studies have investigated a wide variety of cytotoxic antileukemic agents. Most recently, insights into the molecular pathogenesis of AML have led to the development of the more specific targeted therapy. This review focuses on current and evolving drug therapy in the treatment of adults with AML.

Current Treatment Results

Approximately 50-75% of adults with AML achieve complete remission (CR) with the deoxycytidine analog cytarabine and an anthracycline antibiotic such as daunorubicin or idarubicin, or the anthracenedione mitoxantrone, which inhibit the enzyme topoisomerase IIa.
However, only 20-30% of patients enjoy long-term disease-free survival (DFS). The majority of patients die of their disease, primarily due to persistent or relapsed AML. In an ECOG analysis of the outcome of approximately 3,000 patients with previously untreated AML entered on 5 successive clinical trials with cytarabine and daunorubicin for induction and with increasingly more intensive postremission therapy, 62% achieved CR, but 76% relapsed or died.\textsuperscript{3,4} The 5-year overall survival (OS) rate among 2,000 patients less than 55 years has improved from 11% in the 1970s to 37% in the 1990s. (Figures 1a, 1b and 1c) In contrast, among 1,000 patients age 55 years and older, progress over the past 3 decades has been very modest.\textsuperscript{5}

**Prognostic Factors**

The outcome for adults with AML depends on a variety of factors including age of the patient, intensity of postremission therapy, and biologic characteristics of the disease, the most important of which are the cytogenetics at presentation.\textsuperscript{4,6-8} The karyotype of the leukemic cells can distinguish three groups with either favorable, intermediate, or poor prognostic risk.\textsuperscript{6-8} (Figure 2) Other factors include the presence of transmembrane transporter proteins which extrude certain chemotherapy agents from the cell and confer multidrug resistance,\textsuperscript{9} and mutations in or overexpression of specific genes such as WT1\textsuperscript{10,11}, C/EBP\textalpha\textsuperscript{12}, Bax and Bcl-2/Bax ratio\textsuperscript{13}, BAALC\textsuperscript{14}, EVII\textsuperscript{15}, KIT\textsuperscript{16} and FLT3.\textsuperscript{17,18}

**Induction Chemotherapy**

**Development of a Standard Regimen**

During the past 35 years, a series of studies has established an induction regimen which has become a standard of care for patients not participating on a clinical trial. A widely used combination for induction is the cycle specific agent cytarabine 100 mg/m\textsuperscript{2} by continuous...
infusion for 7 days and the non cell cycle specific anthracycline antibiotic daunorubicin 45-60 mg/m²/day intravenously for 3 days. To improve the CR rate, studies have tested alternative and higher doses of anthracyclines or the anthracenediones, higher doses of cytarabine, new agents combined with cytarabine and daunorubicin such as etoposide, the purine analog fludarabine or the camptothecin topotecan, or sequential standard therapy followed by high doses of cytarabine. Despite theoretical advantages, none of these approaches is definitively better than the standard regimen. (Table 1)

**Hematopoietic Growth Factors**

Multiple studies have established the safety of hematopoietic growth factors when administered in induction and consolidation. Growth factors have a role in the supportive care of AML when given after induction therapy to reduce the period of neutropenia. Recently, there has been renewed interest in the use of growth factors as priming agents, to move leukemia cells into a phase of the cell cycle which might render them more susceptible to cytotoxic chemotherapy. However, benefits of such a strategy have not been definitively established. One large study using granulocyte colony-stimulating factor (G-CSF) showed no effect on CR rate, but an improvement in DFS. Another study, also using G-CSF, reported the opposite, an improvement in CR rate, but no effect on DFS. A study with granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no impact on either CR rate or DFS.

**Postremission Therapy**

Various strategies have been explored to eliminate minimal residual disease not apparent in the bone marrow of patients in CR which could contribute to relapse. Such strategies have included intensive consolidation therapy, high-dose chemotherapy or chemoradiotherapy with either
allogeneic or autologous hematopoietic stem cell transplantation (HSCT) or low-dose maintenance therapy

**Intensive Consolidation Chemotherapy**

Retrospective analyses of cooperative group studies and a prospective randomized trial show that increasing the intensity of postremission therapy is beneficial in younger, but not older adults. Several studies have evaluated the role of intensive postremission consolidation with high-dose (3 gm/m²/dose) cytarabine (HiDAC). A prospective study by the Cancer and Leukemia Group B (CALGB) demonstrated that 4 courses of HiDAC are significantly better than 4 courses of intermediate- (400 mg/m²/dose) or standard-dose cytarabine (100 mg/m²/dose) confirming a dose-response effect in younger patients and a benefit in patients with good risk cytogenetics. Cerebellar dysfunction, particularly in older adults and in those with hepatic or renal dysfunction, is an important toxicity.

**General Conclusions About Postremission Consolidation Chemotherapy**

Although postremission therapy is a *sine qua non* for curing AML, fundamental issues remain unresolved. (Table 1) The optimal dose, schedule and number of cycles of consolidation chemotherapy for most patients with AML who achieve CR have not been established. In younger patients, cycles of intensive consolidation chemotherapy, often with, but not limited to, high-doses of cytarabine, prolong DFS and OS.

**Prospective Studies of Intensive Postremission Chemotherapy, Allogeneic Hematopoietic Stem Cell Transplantation, and Autologous Hematopoietic Stem Cell Transplantation (HSCT)**
Hematopoietic stem cell transplantation refers to the administration of very intensive chemotherapy with or without radiation and infusion of previously collected hematopoietic stem cells harvested from either the patient (autologous), or a human leukocyte antigen (HLA) matched donor (allogeneic). Autologous HSCT is limited by the lack of the immunologic reaction referred to as graft-versus-leukemia (GVL) effect present in patients undergoing allogeneic HSCT, in which the donated allogeneic cells recognize the recipient’s leukemic cells as foreign. Furthermore, there is a theoretical risk of infusion of occult residual leukemic cells.\textsuperscript{51} Recently, to decrease toxicities associated with such intensive doses of chemotherapy, lower doses have been explored, relying more on the immunologically mediated GVL effect to eradicate the disease.\textsuperscript{52} While the benefits of this strategy of nonmyeloablative HSCT is currently under investigation,\textsuperscript{52,53} its ultimate role may be in older adults in first CR who are unable to tolerate standard conditioning regimens. Whether such a regimen can reduce the toxicity associated with matched unrelated donor HSCT is currently being explored.\textsuperscript{54} A potential limitation is the 3-9 months required for the immunologic GVL effect to develop in the presence of rapidly proliferating leukemia cells.

Allogeneic HSCT for patients with AML in first CR is associated with the lowest relapse rate and provides the best anti-leukemic potential, but is associated consistently with a higher risk of treatment-related mortality than either autologous HSCT or consolidation chemotherapy.\textsuperscript{55-58} As a result, the benefit of a lower relapse rate is offset by a higher treatment-related mortality. The decision to recommend an allogeneic transplant in first CR must be made on a patient-by-patient basis evaluating the risks and patient age, type of donor match, and disease prognosis. However, it is reasonable to consider such a strategy in patients with poor-risk cytogenetics and some younger patients with intermediate risk cytogenetics who are otherwise suitable candidates.
Current HSCT techniques have changed significantly and the transplant-related mortality with contemporary autologous HSCT is 0-3% compared with 14-18% in published studies, a fact that, historically, has obscured the potential benefit of the lower relapse rate. Furthermore, current understanding of the pathophysiology of AML mandates that therapeutic decisions be made, in part, on cytogenetic and molecular prognostic factors at diagnosis. This has led to subgroup analyses of small patient cohorts that limit confidence in the results.
Maintenance Therapy

Historical and contemporary studies employing various maintenance regimens consistently show a benefit in DFS, but not OS. Further studies are needed to establish a definitive role for this therapeutic modality in AML.

Treatment for Acute Promyelocytic Leukemia

Acute promyelocytic leukemia (APL) is treated differently from all other subtypes of AML and has become the most curable in adults. This subtype is associated with the t(15;17) translocation which results in a fusion transcript, the PML-RARα, derived from the juxtaposition of the PML gene on chromosome 15 and retinoic acid receptor alpha gene on chromosome 17. The vitamin A derivative, all-trans retinoic acid (ATRA) has the remarkable ability to induce differentiation of leukemic promyelocytes in patients with APL which results in high CR rates. Therefore, APL is the first subtype of AML treated with an agent targeted to a specific genetic mutation. The benefits of ATRA in APL were identified as part of Chinese herbal medicine treatments rather than as a conscious effort to target the molecular abnormality in APL. Two prospective randomized trials demonstrate that ATRA with chemotherapy significantly improves DFS and OS and approximately 70% of patients are cured of APL. The concepts that cytarabine may not be required in the treatment of a subtype of AML and that maintenance appears advantageous represent departures from conventional management.

Treatment of Older Adults

The treatment of older adults (ages ≥ 55-60 years) with AML is very disappointing with modest, if any, improvement in OS over the past 4 decades. Older patients do not tolerate intensive
chemotherapy as well as younger patients, particularly if they have preexisting co-morbidities. In addition, older adults frequently have leukemia cells with poor prognosis karyotypes, and frequently express the multidrug resistance marker P-glycoprotein rendering their cells more resistant to chemotherapy. It is possible that multidrug resistance marker expression identifies an immature stem cell-like leukemia. Historical studies using attenuated doses of chemotherapy or delaying intensive therapy until disease progression led to poor results. Contemporary studies in older patients have established that approximately half can achieve CR. The major problem is that older adults have a high rate of relapse and OS rates are less than 10%. No clearly effective postremission therapy has been established. Considering that AML occurs much more frequently in older patients, this represents the most important challenge in drug therapy of AML. The discouraging overall outcome in older adults has spurred major efforts in the development of new targeted drug therapies.

Treatment of Patients with Relapsed or Refractory AML

The treatment of adults with relapsed or refractory AML is also unsatisfactory. The most important factor predicting response to re-induction chemotherapy appears to be the duration of first CR. High-dose cytarabine has been an effective re-induction regimen. However, the addition of other agents to HiDAC does not improve outcome. Allogeneic HSCT may provide the highest likelihood of cure, presumably related to the generation of an immunologically-mediated graft-versus-leukemia reaction not present with salvage chemotherapy, preferably after induction of a second CR. However, there is a lack of prospective data to definitively demonstrate a superior outcome with such a strategy. If a suitable histocompatible sibling donor is not available, transplantation from an alternative donor such as a matched unrelated donor or a haploidentical stem cell donor can be considered. However, given the risks of reactivation...
of CMV and other opportunistic infections, this strategy is still investigational. A small number of patients in second CR also may be cured with autologous HSCT. Standard chemotherapy alone is rarely curative in patients who have relapsed. Most of these patients, as well as older adults who have not relapsed, but who have a poor prognosis, are candidates for novel investigational approaches. (Table 3) Much of the search for new agents focuses on biologically targeted strategies which may be effective without the severe myeloablative toxicity that, historically, has been the hallmark of drug therapy for AML.

**Insights into Novel Therapy based on Genetic Mechanisms of Disease**

There is more known about the genetic basis of AML than perhaps any other human cancer. More than 100 different mutations and/or gene rearrangements have been identified in AML. Because AML is a sporadic disease, only rarely occurring as a heritable trait, many of the initial insights were derived from cloning of acquired recurring chromosomal translocations from bone marrow of affected individuals. More recently, a spectrum of sub-cytogenetic point mutations and gene rearrangements have been identified through characterization of candidate loci, and it is likely that many more will be identified.

*Mutations that activate signal transduction cascades in AML*

From a therapeutic perspective, these mutations can be subdivided into several subgroups. For example, a majority of AML patients have mutations that result in constitutive activation of signal transduction pathways that confer proliferative and/or survival advantage to hematopoietic progenitors (Table 2). These include mutations that constitutively activate receptor tyrosine kinases, such as FLT3 or KIT, oncogenic mutations in RAS, or activating mutations in protein tyrosine phosphatases such as PTPN11 (SHP2). These appear to segregate as a complementation group, in that only very rarely are any two of these observed in the same AML patient. Thus, as
discussed below, small molecule inhibitors of these pathways such as FLT3 or KIT inhibitors, or inhibitors of RAS through farnesyl transferase inhibition, are attractive as potential therapeutic agents. These mutations collectively account for ~50% of AML patients, but it is plausible that high-throughput genomic approaches to gene discovery will ultimately identify activating mutations in signal transduction pathways in all patients with AML. In addition, the high frequency of mutations in signal transduction pathways suggests that small molecule inhibitors of common downstream effectors shared by all mutations may also be effective (e.g. MEK inhibitors to impair oncogenic RAS signals, or mTOR with rapamycin as a target for PI3K/AKT activation\textsuperscript{86}). Such agents could be used alone or in combination with inhibitors of upstream effectors such as FLT3.

\textit{Mutations in genes that result in dysregulated gene transcription}

A second broad complementation group of mutations and gene rearrangements is defined by loss of function mutation in transcription factors and transcriptional co-activators that are important for normal hematopoietic development. These mutations also rarely if ever are present in the same patient with leukemia, and appear to confer the property of impaired hematopoietic differentiation to leukemic blasts, and may contribute to self-renewal potential, a hallmark of all human cancers. Novel therapeutic approaches have focused on compounds that might override the block in differentiation, as exemplified by the paradigm of ATRA therapy for APL. The mechanistic basis for therapeutic efficacy of ATRA in APL is complex, but the phenotypic consequence of ATRA therapy is induction of terminal differentiation and apoptosis of leukemic blasts. A key component of ATRA activity is release of the nuclear co-repressor complex, containing histone deacetylase (HDAC), that is aberrantly recruited to promoters by the PML-RAR\textsubscript{α} fusion.\textsuperscript{87} Aberrant recruitment of nuclear co-repressor complexes by leukemogenic fusion proteins appears to be a central theme in AML. For example, RUNX1-ETO and CBFB-MYH11
associated with t(8;21) and inv(16) respectively, aberrantly recruit the nuclear co-repressor complex to RUNX1 target genes.\textsuperscript{88-90} Thus, development of small molecule inhibitors of HDAC may be of therapeutic value in induction of differentiation, and that they might be used in combination with agents that target signal transduction pathways. Other loss of function mutations that impair hematopoietic differentiation and are potential targets for therapy are listed in Table 2, and may involve the hematopoietic transcription factors RUNX1, GATA-1, C/EBP\(\alpha\), and PU.1, as well as mutations that affect components of the transcriptional apparatus itself, such as MLL fusions and fusions involving transcriptional co-activators. In addition, there is evidence for overexpression of certain transcription factors such as EVI1 in AML as a consequence of the t(3;21) translocation\textsuperscript{91,92}, or through as yet unidentified trans- or cis-acting mutations. Overexpression of EVI1 also results in a myelodysplastic phenotype in murine models of disease, suggesting that it may be a viable target for therapeutic intervention.\textsuperscript{93}

Finally, there are several mutations that occur in genes that encode proteins involved in nuclear cytoplasmic shuttling. These include direct involvement of components of the nuclear pore, such as the NUP98 gene that is fused through chromosomal translocation to a spectrum of partners, including HOX family members,\textsuperscript{94} and the NUP214 gene that is fused to DEK in t(6;9) AML patients. Although the fusion partners must play an important role in disease pathogenesis, it also seems likely that the frequent selection for fusions containing components of the nuclear pore in AML must also connote a functional relevance for the nucleoporins themselves. Most recently, it has been reported that nucleophosmin (NPM), a nucleolar protein that is involved in nucleocytoplasmic shuttling, is mutated and mislocalized to the cytoplasm of AML cells in \(\sim\)35\% of patients.\textsuperscript{95} It is not known what the functional consequence of this observation is, but it again suggests that dysregulation of the normal nuclear to cytoplasmic trafficking machinery may be important in pathogenesis of AML.
Recently, attention has turned to the self-renewal potential of leukemic cells as a therapeutic target. A small population of blasts has been identified in human AML that has the properties of leukemic stem cells, and is thought to be responsible for continuous growth and propagation of leukemia blasts, and for relapse of disease in patients after remission induction with intensive chemotherapy. Several genes and pathways have been identified that are important for this critical property of self-renewal, including the WNT/β-catenin pathway, Notch, BMI-1, and HOX family members. Although it is not yet certain how these pathways might be effectively targeted therapeutically, or whether it will be possible to target these pathways without excessive toxicities, these are ultimately the most important target cells to ablate (Figure 3).

**New Agents Directed at Molecular and Other Specific Targets**

Among the most exciting developments has been the remarkable ability to classify subtypes of AML by characterizing the expression profiles of all known genes in the human genome using microarray technology. The expression profile of clusters of genes will be useful not only to classify patients, but may also identify specific molecular targets for therapeutic intervention. Currently, cytogenetics at presentation provides the most important prognostic information in AML. However, 70% of patients are in the intermediate risk category and, of these, about 70% have a normal karyotype. Therefore, the most common karyotype in AML -normal- is a large, heterogeneous and poorly defined population. Expression profiling has already refined the diagnostic classification of leukemias and holds promise for individualized approaches to therapy.

Some targets to which therapy has already been directed include cell surface antigens such as CD33, a glycoprotein expressed on most AML blast cells and not on normal hematopoietic stem cells; P-glycoprotein, a mediator of multidrug resistance which acts as an efflux pump to extrude chemotherapy from the cell; enzymes involved in signal transduction such as farnesyl...
transferase; vascular endothelial growth factor and other angiogenic proteins; enzymes that contribute to the enhanced proliferative/survival capacity of leukemia blasts, such as FLT3 or RAS; enzymes that contribute to impaired hematopoietic differentiation such as HDAC inhibitors, and the antiapoptotic gene bcl-2. While these new strategies have not yet translated into the kind of clinically meaningful advances as has ATRA in APL, they represent a first wave of targeted therapies in AML, and provide a platform for development of more efficacious targeted therapies. In addition, it is likely that none of these will be curative as single agents in treatment of this complex disease, but rather will need to be used in combination with conventional therapy (as is ATRA) or with other molecularly targeted agents.

**Gemtuzumab ozogamicin**

The first of these new targeted agents to be approved by the US Food and Drug Administration is gemtuzumab ozogamicin. This agent is an immunoconjugate of an anti-CD33 antibody chemically linked to a potent cytotoxic agent, calicheamicin. Complete remission by conventional criteria is achieved in approximately 15% of patients with AML in first relapse. Occasional patients have developed a veno-occlusive disease-like syndrome and caution is indicated for those patients proceeding to transplant. Two recent studies suggest that gemtuzumab ozogamicin may be associated with a higher CR rate when administered with intensive chemotherapy and major cooperative groups are conducting Phase III studies which incorporate gemtuzumab ozogamicin as part of standard chemotherapy in newly diagnosed patients with AML. If randomized clinical trials confirm these findings, the standard of care for induction in AML will change for the first time in 30 years. Attempts to offer gemtuzumab ozogamicin to older adults as initial induction therapy have not been encouraging. There
are data that suggest that the effects of gemtuzumab ozogamicin may be potentiated by the use of a p-glycoprotein inhibitor.113

**Multidrug Resistance Inhibitors**

Although several agents inhibit P-glycoprotein, with the exception of a SWOG trial testing cyclosporine given with cytarabine and infusional daunorubicin,114 randomized trials of MDR modulators such as PSC-833 have not shown benefit.115,116 It is also possible that expression of multidrug resistance simply identifies an immature stem cell-like leukemia. More potent modulators such as Zosuquidar are currently being studied.117

**Farnesyl transferase inhibitors**

Mutations and dysregulation of Ras have been associated with the development of myeloid leukemias.118 Farnesyltransferase inhibitors (FTI) interfere with Ras signaling by precluding farnesylation of Ras and transfer to the plasma membrane.119 These agents have activity in refractory AML120 and are modestly active in newly diagnosed patients.121 Responses do not correlate with mutational status of Ras, which suggests that activation of native Ras by upstream effectors (such as mutant FLT3) might also be of therapeutic value. However, in some cases response does not even correlate with the degree of FT inhibition, suggesting that there may be other important targets. Preliminary data reporting a CR rate of 21% in 92 newly-diagnosed patients has led to a current major intergroup trial evaluation of the FTI Zarnestra in older adults who are unable to tolerate conventional chemotherapy.

**Histone deacetylase and proteosome inhibitors**
Aberrant recruitment of the nuclear co-repressor complex by leukemogenic fusion proteins is a recurring theme in AML, and may result both in modification of chromatin structure at critical hematopoietic promoters, as well as aberrant acetylation of proteins that regulate cell cycle progression and other functions.\textsuperscript{122} HDAC inhibitors induce differentiation of malignant cells and are under active investigation in AML.\textsuperscript{123,124}

The proteosome inhibitor bortezomib, a newly approved drug for multiple myeloma, has demonstrated preclinical synergistic activity with the histone deacetylase inhibitors, as well as potential single agent activity in leukemia.\textsuperscript{125,126} Clinical efficacy in AML is intriguing, although as yet, unproven.

**Antiangiogenesis agents**

The potential role for antiangiogenesis therapy in AML is suggested by evidence that bone marrow biopsies for patients with AML demonstrate increased microvessel density which is associated with a poor prognosis.\textsuperscript{127} Furthermore, vascular endothelial growth factor (VEGF) plays a role in stimulating growth and proliferation of leukemic cells and an increased endogenous level of VEGF is also associated with a poor prognosis.\textsuperscript{128} Receptor tyrosine kinase inhibitors of VEGF are another strategy under active study.\textsuperscript{129} Preliminary data suggest that SU5416, a small molecule inhibitor of phosphorylation of VEGF receptors 1 and 2, C-Kit, the SCF receptor and FLT 3, has activity in AML.\textsuperscript{130} Bevacizumab, an anti-VEGF antibody, has been demonstrated to be safe in AML and is currently undergoing phase II studies.\textsuperscript{131}
**FLT3 inhibitors**

Mutations that constitutively activate the FLT3 receptor tyrosine kinase occur in ~30% of AML, and confer a poor prognosis. These observations have fueled the development of FLT3-selective targeted tyrosine kinase inhibitors with in vitro cytotoxicity to leukemia cells.

There are four FLT3 inhibitors that are currently in clinical trials, including PKC-412 (Novartis), CEP-701 (Cephalon), MLN518 (Millennium) and SU11248 (SuGen). Although data are still preliminary, several generalizations have emerged. The compounds, which like imatinib, are selective but not completely specific, are well tolerated at doses that achieve inhibition of the target FLT3. Each of the inhibitors have activity in relapsed AML patients with activating mutations, although responses have been quite modest and characterized by transient reduction in peripheral blood blasts, less frequent reduction in bone marrow blasts, and rare hematologic responses. In some cases, patients that lack ITD or activation loop mutations have responded to FLT3 inhibitors, though mutations that activate FLT3 outside of these regions have been identified, and may explain response in this subset. These data are perhaps not surprising, in that it would not be expected that a kinase inhibitor as a single agent in this setting would be any more effective than imatinib in CML blast crisis patients. Current clinical trials are focusing on use of FLT3 inhibitors in combination with chemotherapy.

Activating alleles of KIT occur in ~5% of AML patients, but in contrast with activating juxtamembrane deletions observed in gastrointestinal stromal cell tumors that are imatinib sensitive, the most common KIT alleles in AML include KIT D816V or KIT D816Y that are resistant to imatinib. It has recently been reported that PKC-412, however, is a potent inhibitor of these mutant KIT proteins, and may have clinical therapeutic value for these AML patients, as well as in systemic mast cell disease associated with KIT D816V or KIT D816V.
Apoptosis inhibitors

Overexpression of the apoptosis inhibitor protein bcl-2 can render tumor cells resistant to induction of apoptosis by drug therapy. A high level of expression of bcl-2 in AML is associated with a poor prognosis. Downregulation of bcl-2 by antisense oligonucleotides in vitro sensitizes leukemic cells to chemotherapy in AML cell lines. A phase I trial of bcl-2 antisense oligonucleotide (GNS, oblimersen sodium) showed a response in 8 of 20 patients with relapsed or refractory AML. In a subsequent phase I trial in untreated older adults, to determine feasibility, the bcl-2 antisense oligonucleotide was administered with chemotherapy. Ten of 26 patients (45%) achieved CR without unexpected toxicities. A randomized phase III study by the CALGB is now evaluating the role of the bcl-2 antisense oligonucleotide both in induction and in consolidation.

Summary and Future Directions

Consistent incremental progress has occurred in younger adults with AML because increasingly intensive chemotherapy can be administered to patients whose cells are relatively sensitive. Older adults usually cannot tolerate such intensive chemotherapy and their leukemic cells are inherently more resistant. Many new antileukemic agents with novel mechanisms of action and direction are available to explore.

Several of the current new agents being investigated are likely to have a role in the future therapy of AML. However, diverse drug resistance mechanisms are a prominent feature of AML and none alone appear likely to alter the standard of care and have an impact comparable to that of ATRA in APL. Combinations of several agents, targeting more than one gene mutation or antigenic determinant may hold greater promise. The future also rests with new techniques such
as cDNA microarray,$^{102-105,139}$ and genome-wide approaches to gene discovery, in combination with high-throughput screens for modulators of validated targets. These technologies will likely provide important insights into the molecular pathogenesis of AML and identify critical genes that may be targeted.

Acknowledgments

The authors thank Dr. Charles Schiffer for his review of the manuscript and Ms. Kristen Burton for her assistance with manuscript preparation.
### Table 1a

**Therapeutic Strategies in AML**

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Induction</strong></td>
<td>• Optimal dose of anthracycline is unknown</td>
</tr>
<tr>
<td></td>
<td>• No definitive evidence that any anthracycline or the anthracenedione mitoxantrone is better at any age</td>
</tr>
<tr>
<td>Daunorubicin 45 mg – 60 mg/m² for 3 days or alternative anthracycline or the anthracenedione mitoxantrone</td>
<td>• Standard regimen is effective in all cytogenetic subtypes</td>
</tr>
<tr>
<td>with</td>
<td>• No evidence that addition of HiDAC or etoposide essential</td>
</tr>
<tr>
<td>Cytarabine 100 mg/m² for 7 days</td>
<td>• The induction regimen should not be attenuated for older adults</td>
</tr>
<tr>
<td><strong>Post Remission</strong></td>
<td>• Essential for curing AML</td>
</tr>
<tr>
<td></td>
<td>• Clearly benefits younger (&lt; 55-60 years) adults</td>
</tr>
<tr>
<td>High-dose cytarabine</td>
<td>• Optimal dose, schedule and number of cycles of HiDAC unknown</td>
</tr>
<tr>
<td>HiDAC 1-3 g/m² over 1-3 hours for 3-6 days x 1-4 cycles</td>
<td>• Although HiDAC clearly effective, groups using different intensive regimens have reported similar data</td>
</tr>
<tr>
<td>Maintenance therapy</td>
<td>• Standard of care in APL. Role in other subtypes less convincing</td>
</tr>
<tr>
<td>Stem cell transplantation</td>
<td>• Most potent antileukemic strategy, but caution warranted in interpretation of studies that are under-powered and often not applicable to current practice</td>
</tr>
<tr>
<td><strong>Table 1b</strong></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Relapsed or Refractory AML</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Strategy</strong></th>
<th><strong>Comments</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy</td>
<td>• Rarely curative in any subtype.</td>
</tr>
</tbody>
</table>
| Effective reduction in leukemia cell burden | • Essential for cure.  
• High dose cytarabine most effective.  
• No evidence that additional drugs are beneficial.  
• May be effective even if prior exposure to cytarabine in induction or consolidation.  
• Best if long first CR (more than 6-12 months).  
• Investigational approach is appropriate if short CR 1 or refractory. |
| Allogeneic transplant | • Potentially curative.  
• Best results if in second CR or in early first relapse. |
| Autologous transplant | • Few reports of cure.  
• Best results if in second CR with previously harvested stem cells. |
| Palliative care | • Appropriate for older adults not eligible for curative approaches. |
### Table 2

**Genetic Insights into Targeted Therapy**

<table>
<thead>
<tr>
<th>Signal Transduction Pathways</th>
<th>Mutation</th>
<th>Potential Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLT3</td>
<td>activation loop</td>
<td>~5-10%</td>
</tr>
<tr>
<td></td>
<td>ITD</td>
<td>~20-25%</td>
</tr>
<tr>
<td>RAS</td>
<td>~10-15%</td>
<td>farnesyl transferase inhibitors</td>
</tr>
<tr>
<td>PTPN11 (SHP2)</td>
<td>rare</td>
<td>imatinib</td>
</tr>
<tr>
<td>BCR-ABL</td>
<td>rare</td>
<td>imatinib</td>
</tr>
<tr>
<td>TEL-PDGFβR</td>
<td>rare</td>
<td>small molecule FGFR inhibitors</td>
</tr>
<tr>
<td>ZNF198-FGFR1</td>
<td>rare</td>
<td></td>
</tr>
</tbody>
</table>

**Downstream Effectors**

|                   |         |                 |
|                   |         | rapamycin       |
| mTOR              |         | small molecule inhibitors |
| MEK               |         | small molecule inhibitors |
| PI3/AKT           |         | small molecule inhibitors |

<table>
<thead>
<tr>
<th>Differentiation Pathways</th>
<th>Mutation</th>
<th>Potential Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>PML-RARα</td>
<td></td>
<td>ATRA, arsenic</td>
</tr>
<tr>
<td>Core Binding Factor</td>
<td></td>
<td>HDAC inhibitors</td>
</tr>
<tr>
<td>RUNX1-ETO</td>
<td></td>
<td>HDAC inhibitors/differentiating agents</td>
</tr>
<tr>
<td>CBFβ-MYH11</td>
<td></td>
<td>HDAC inhibitors/differentiating agents</td>
</tr>
<tr>
<td>MLL fusions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-activator fusions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>e.g. MLL-CBP, MOZ-TIF2</td>
<td></td>
<td>differentiating agents</td>
</tr>
<tr>
<td>RUNX1, GATA-1, C/EBPα, PU-1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Self-renewal pathways</th>
<th>Pathway/gene</th>
<th>?</th>
</tr>
</thead>
<tbody>
<tr>
<td>WNT/β-catenin</td>
<td></td>
<td>?</td>
</tr>
<tr>
<td>Notch</td>
<td></td>
<td>?</td>
</tr>
<tr>
<td>Bmi-1</td>
<td></td>
<td>?</td>
</tr>
<tr>
<td>HOX genes</td>
<td></td>
<td>?</td>
</tr>
<tr>
<td>New Agents</td>
<td>Targets</td>
<td>Comments</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>---------------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>All-trans retinoic acid</td>
<td>PML-RARα</td>
<td>Has changed standard of care in APL. Improves DFS and OS in newly diagnosed patients.</td>
</tr>
<tr>
<td>Arsenic Trioxide</td>
<td>PML-RARα</td>
<td>Has changed standard of care in relapsed APL; induces high rate of hematologic and molecular CR; may cure some patients.</td>
</tr>
<tr>
<td>Gemtuzumab ozogamicin</td>
<td>CD33</td>
<td>Modestly effective in patients with relapsed AML; role as additional agent in standard therapy currently being investigated.</td>
</tr>
<tr>
<td>Farnesyltransferase inhibitor</td>
<td>Farnesylation of lamin A and HJJ-2</td>
<td>Modestly effective in high risk newly diagnosed patients; role as adjunct to standard therapy under investigation.</td>
</tr>
<tr>
<td>MDR modulators; Cyclosporine, PSC833, Zosuquidar</td>
<td>P-glycoprotein and other multidrug resistance proteins</td>
<td>In general, results disappointing.</td>
</tr>
<tr>
<td>Histone deacetylase inhibitors; Phenylbutyrate, Depsipeptide</td>
<td>Histone deacetylase</td>
<td>Clinical trials underway.</td>
</tr>
<tr>
<td>Bcl-2 antisense dinucleotide</td>
<td>Bcl-2 protein</td>
<td>Clinical trials underway.</td>
</tr>
<tr>
<td>Antiangiogenic agents</td>
<td>Vascular endothelial growth factor</td>
<td>Clinical trials underway.</td>
</tr>
</tbody>
</table>
Figure 1a

Survival

Years

n=2985, Median Survival=12.1 Months, 5-Year Survival=22%
Figure 1b

Study Year: 1973-1979, n=454, Median Survival=11.3 Months, 5-Year Survival=11%

Study Year: 1983-1986, n=499, Median Survival=13.4 Months, 5-Year Survival=24%

Study Year: 1989-1997, n=1044, Median Survival=20.6 Months, 5-Year Survival=37%
Figure 1c

Study Year: 1989-1997, n=553, Median Survival=6.2 Months, 5-Year Survival=12%

Study Year: 1983-1986, n=142, Median Survival=6.3 Months, 5-Year Survival=13%

Study Year: 1973-1979, n=293, Median Survival=3.5 Months, 5-Year Survival=6%
Figure 2

Heterogeneity of 3 groups: $p < .0001$
Figure 3

Therapeutic Targets in Leukemia

Proliferation/survival mutations, do not affect differentiation

- FLT3-ITD
- Oncogenic RAS
- KIT alleles
- PTPN11

Mutations associated with impaired differentiation, self-renewal

- Core binding factor (CBF)
- Retinoic acid receptor α
- MLL rearrangements
- Co-activators (CBP, TIF2)
- RUNX1, GATA-1, C/EBPα

FLT3 inhibitors
Others

Acute Leukemia

Targeting self-renewal: WNT, Notch, Bmi-1, Hox

ATRA
?HDAC inhibitors
Figure Legends

**Figure 1a** Kaplan-Meier product-limit estimate of overall survival for patients with newly diagnosed acute myeloid leukemia treated on ECOG protocols between 1973-1997. Reprinted with permission.5

**Figure 1b** Kaplan-Meier product-limit estimate of overall survival for younger patients (ages ≤ 55 years) with newly diagnosed acute myeloid leukemia treated on ECOG protocols between 1973-1997. Reprinted with permission.5

**Figure 1c** Kaplan-Meier product-limit estimate of overall survival for older patients (ages > 55 years) with newly diagnosed acute myeloid leukemia treated on ECOG protocols between 1973-1997. Reprinted with permission.5

**Figure 2** Estimated distributions of overall survival by cytogenetic risk status. Reprinted with permission.8

**Figure 3** There are two broad classes of mutations associated with acute leukemia. One class of mutations, exemplified by activating mutations in tyrosine kinases such as BCR/ABL, FLT3, TEL/PDGFβR, or oncogenic Ras mutations result in enhanced proliferative and survival advantage for cells. These mutations can be targeted by small molecule inhibitors of the respective tyrosine kinases, or potentially by farnesyl transferase inhibitors. A second class of mutations is loss of function mutations in hematopoietic transcription factors, as exemplified by the AML1/ETO or PML/RARα gene rearrangements, or point mutations in AML1 or C/EBPα. Treatment that targets this class of mutations can include agents that specifically induce differentiation and apoptosis of leukemic cells, as demonstrated by the use of ATRA in PML/RARα positive acute promyelocytic leukemia, and potentially by HDAC inhibitors. Finally, although not known to be mutant in leukemia, genes and pathways that are responsible for the self-renewal potential of leukemia stem cells, such as WNT, Notch, Bmi-1 or HOX family members may also be candidates for molecularly targeted therapy.
References


Drug therapy of acute myeloid leukemia

Martin S Tallman, D G Gilliland and Jacob M Rowe